Belite Bio, Inc (BLTE) Fair Value 2026

BLTE · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, Belite Bio, Inc (BLTE) trades at $151.72. QOC: 5.0/10. Value Trap Risk: 42/100 (WARN). 1/13 models active.

Key Facts

Ticker
BLTE
Price
$151.72
Quality Score
5.0/10
Value Trap Risk
42/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give BLTE?

1 Intrinsic Value Models vs. Current Price ($151.72)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $12.76 -91.6%

All Models Active

All 1 models are displayed above.

What Is Belite Bio, Inc (BLTE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Belite Bio, Inc's intrinsic value is estimated at $12.76, suggesting the stock is overvalued at its current price of $151.72. With 1 out of 1 models flagging downside (-91.6% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About BLTE?

1 of 13 models are currently active for BLTE. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does BLTE Rank in Biotechnology?

Among 625 Biotechnology stocks, BLTE ranks #307 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Belite Bio, Inc operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating BLTE should weigh these sector-specific dynamics alongside our model-derived fair values.

Is BLTE a Value Trap?

CirclFi's Value Trap algorithm assigns BLTE a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Belite Bio, Inc. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Belite Bio, Inc's fundamental quality profile registers 5.0/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BLTE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BLTE's 1 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Belite Bio, Inc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ZBIOZenas BioPharma, Inc.QOC 5.0IMMXImmix Biopharma, Inc.QOC 5.0CADLCandel Therapeutics, Inc.QOC 5.0ACIUAC Immune SAQOC 5.0ATYRaTyr Pharma, Inc.QOC 5.0GERNGeron CorporationQOC 5.0ELVNEnliven Therapeutics, Inc.QOC 4.5PPBTPurple Biotech LtdQOC 2.1NUVBNuvation Bio Inc.QOC 6.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ZBIO · IMMX · CADL · ACIU · ATYR · GERN · ELVN · PPBT · NUVB · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to BLTE?

5 companies across all industries closest to BLTE’s Quality of Company score of 5.0/10.

RDZNRoadzen, Inc.QOC 5.0RPMTRego Payment Architectures, Inc.QOC 5.0INHDInno Holdings Inc.QOC 5.0XXII22nd Century Group, Inc.QOC 5.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RDZN · RPMT · INHD · XXII · NVDA

Where Does BLTE Sit in CirclFi's Biotechnology Rankings?

BLTE is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Belite Bio, Inc’s Valuation?

What is Belite Bio, Inc's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Belite Bio, Inc (BLTE). The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BLTE overvalued or undervalued right now?

At $151.72, 0 of 1 active models suggest BLTE may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Belite Bio, Inc's business model in Biotechnology.

What does a Quality of Company score of 5.0 mean for BLTE?

Belite Bio, Inc's QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BLTE?

CirclFi analyzes BLTE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BLTE a value trap in 2026?

Belite Bio, Inc's Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Belite Bio, Inc (BLTE) a Quality of Company score of 5.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/BLTE/ · Methodology
Primary sources for this BLTE valuation
  • Financial statements: Belite Bio, Inc 10-K and 10-Q filings on SEC EDGAR (CIK 0001889109) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BLTE as of ; valuations recomputed .